Sunday, 6 November 2005

SUNDAY, 6 NOVEMBER 2005
8:00 - 12:00	Pre-Meeting Short Courses
	Sunday Short courses
12:00 - 13:00	Grand Opening & Contributed Poster Viewing
13:00 - 13:30	Welcome from the ISPOR President
	Peter Neumann ScD, ISPOR 2005-2006 President and Associate Professor of Policy and Decision Sciences, Harvard School of Public Health, Boston, MA, USA Introduction and Congress Objectives Program Committee Co-Chairs: Patrizia Berto PharmD, MBA, President, PBE Consulting, Verona, Italy; Lorenzo G Mantovani MSc, DSc, Director, Center of Pharmacoeconomics, School of Pharmacy, University of Milan, Milan, Italy ISPOR 10 YEARS - “Past, Present and Future”
13:30 - 15:00	First Plenary Session
	Patient Values and Societal Values: How to Measure and Compare Outcomes and What Considerations for the Different Audiences Speakers: Paul Kind, Principal Investigator, Centre for Health Economics, University of York, York, UK; Mandy Ryan PhD, Professor in Health Economics & Director of the Valuation and Implementation Programme, Health Economics Research Unit, University of Aberdeen, Aberdeen, UK; Claude Le Pen PhD, Scientific Director, Aremis Consultants, Neuilly Sur Seine, France This plenary session will discuss what represents value for the patient (better QoL, less side-effects) that could be dramatically different from what represents value for the society (general morbidity, mortality). This translates into different messages for different audiences (payers, physicians, patient associations, individuals).
15:00 - 15:30	Break
15:30 - 16:30	Contributed Workshops Session I - See all workshops details
	CLINICAL STUDY METHODOLOGY ISSUES W1: EXPOSURE PROPENSITY SCORES: CONCEPTS, APPLICATIONS, AND PRACTICAL CONSIDERATIONS Discussion Leaders: Almut G Winterstein PhD, Assistant Professor, Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA; Abraham G Hartzema MSPH, PhD, Eminent Scholar, Dpt. of Pharmacy Healthcare Administration, University of Florida, Gainesville, FL, USA; Tobias Gerhard BS, Pharmacy Health Care Administration, University of Florida, Gainesville, FL, USA ADHERENCE/COMPLIANCE ISSUES W2: METHODS FOR MEDICATION COMPLIANCE STUDIES: PATIENT COMPLIANCE AS A PREDICTOR OF CLINICAL AND ECONOMIC OUTCOMES Discussion Leaders: Michael Nichol PhD, Associate Professor & Chair, University of Southern California, Dept of Pharm Econ & Policy, Los Angeles, CA, USA; Femida Gwadry-Sridhar PharmD, PhD, Researcher, McMaster University, London, ON, Canada; JB Benner PharmD, ScD, Principal, ValueMedics Research, Falls Church, VA, USA COST STUDY METHODOLOGY ISSUES W3: METHODS FOR PRESENTING PROBABILISTIC SENSITIVITY ANALYSES FOR EFFECTIVE COMMUNICATION OF FINDINGS Discussion Leaders: Douglas CA. Taylor MBA, Associate Director, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA; Lisa J. McGarry MPH, Associate Director, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA; David Thompson PhD, Managing Director, U.S. Operations, Health Economics & Outcomes Research, Innovus Research (U.S.) Inc, Medford, MA, USA HEALTH CARE COVERAGE AND REIMBURSEMENT ISSUES W4: CASE STUDIES IN PERSONALIZED MEDICINE: VALUE CREATION AND REWARDS-INCENTIVES AND IMPLICATIONS Discussion Leaders: Louis Garrison PhD, Professor, Department of Pharmacy, University of Washington, Seattle, WA, USA; Adrian Towse MA, Director, Office of Health Economics, London, UK; David L Veenstra MD, University of Washington, Department of Pharmacy, Seattle, WA, USA HEALTH CARE POLICY DEVELOPMENT ISSUES W5: MULTI-NATIONAL ASSESSMENT OF OUTCOMES VIA RETROSPECTIVE DATABASES Discussion Leaders: Vittorio Maio PharmD, MSPH, Assistant Professor, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Elaine J. Yuen PhD, MBA, Research Assistant Professor, Center for Research in Medical Education and Health Care, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Diana Brixner PhD, Associate Professor, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA; Gary M Oderda PharmD, MPH, Professor, Pharmacotherapy Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT, USA; Carl Asche MBA, MSc, PhD, Associate Professor, University of Utah, Salt Lake City, UT, USA; Kenneth D. Smith, PhD, Research Assistant Professor, Department of Health Policy, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA, USA; Steve Morgan, PhD, Assistant Professor, Centre for Health Services & Policy Research, University of British Columbia, Vancouver, BC, Canada W6: A NEW APPROACH TO HTA - A COMPUTERIZED MODEL Discussion Leaders: Ifat Abadi-Korek PhD, Pharmacoeconomics Researcher, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy research, Ramat Gan, Israel; Orly Tamir MSc, Health Technology Assessment & Research, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy research, Ramat Gan, Israel; Ishay Ostfeld MD, Israeli Center for Technology Assessment in Health Care (ICTAHC), The Gertner Institute for Epidemiology & Health Policy research, Ramat Gan, Israel. PREFERENCE-BASED STUDIES W7: DISCRETE CHOICE EXPERIMENTS IN HEALTH POLICY AND DECISION MAKING Discussion Leaders: Mandy Ryan MSc, PhD, Professor of Health Economics, Health Economics Research Unit, Aberdeen University, University Medical Building,Aberdeen, UK; Mark Sculpher PhD, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK; Lorenzo G Mantovani EconD, MSc, DSc, Head of Research, Center of Pharmacoeconomics, University of Milan, Milan, Italy QOL/PRO METHODOLOGY ISSUES W8: WHAT REALLY ARE PATIENT-REPORTED OUTCOMES? Discussion Leaders: Judith Barr MEd, ScD, Associate Professsor and Director, Northeastern University, National Education and Research Center for Outcomes Assessment, Boston, MA, USA; Laurie Burke RPh, MPH, Director, Study Endpoints and Label Development, Food and Drug Administration, Rockville, MD, US; Pennifer Erickson PhD, Co-founder, O.L.G.A, State College, PA, USA
16:30 - 17:00	Break
17:00 - 18:00	Contributed Podium Presentations - Session I (4 podium groups with 4 presentations per group)
	Development Of Methods And Concepts In Outcomes Research Statistics MC1 USE OF A MODIFIED RECURSIVE PARTITIONING AND AMALGAMATION (RECPAM) TECHNIQUE IN OUTCOMES RESEARCH Katz LM1, Doyle JJ1, Bergemann R2, Siegartel LR1, Stern L1, Chalfin D3, Danis M4, Rapoport J5, Levy M6 1 Analytica International, New York, NY, USA; 2 Analytica International, Loerrach, Germany; 3 Montefiore Medical Center, Port Washington, NY, USA; 4 National Institutes of Health, Bethesda, MD, USA; 5 Mount Holyoke College, South Hadley, MA, USA; 6 Brown University, Providence, RI, USA MC2 IMPACT OF THE PROPENSITY SCORE ESTIMATION METHOD WHEN MATCHING PATIENTS TO REDUCE RECRUITMENT BIAS IN OBSERVATIONAL STUDIES Riou França L, Payet S, Le Lay K, Launois R REES France, Paris, France MC3 METAMODELLING FOR THE CALCULATION OF THE EXPECTED VALUE OF PERFECT INFORMATION ON INDIVIDUAL MODEL PARAMETERS Oostenbrink JB, Rutten-van Molken MP Erasmus MC, Rotterdam, Netherlands MC4 UNCONDITIONAL POWER FOR SECONDARY OBJECTIVES IN A CLINICAL TRIAL Wang J, Irish WD RTI Health Solutions, Research Triangle Park, NC, USA Cost Evaluation Studies In Cardiovascular Diseases CV1 ATRIAL BASED PACING DECREASES ATRIAL FIBRILLATION RELATED HOSPITALIZATIONS AND COSTS IN BRADY-TACHY SYNDROME Ruciñski P1, Kutarski A1, Latek M2, Kamiñski B2, Szczasny M1, Widomska-Czekajska T1, Wdowiak L1 1 Medical University of Lublin, Lublin, Lubelskie, Poland; 2 Warsaw School of Economics, Warszawa, Mazowieckie, Poland CV2 COSTS OF CARDIOVASCULAR DISEASE: A CASE-CONTROL STUDY De Portu S1, Monzini M2, Mazzarotto E3, Galletti M3, Mantovani LG2 1 University of Naples, Naples, Italy; 2 Center of Pharmacoeconomics, Milan, Italy; 3 University of Naples, Naples, Italy CV3 A COST-EFFECTIVENESS ANALYSIS OF CANDESARTAN IN THE TREATMENT OF CHRONIC HEART FAILURE Lamotte M1, Annemans L1, Schockaert B2 1 IMS Health, Brussels, Belgium; 2 Astrazeneca, Brussels, Belgium CV4 DISCRETE EVENT SIMULATION OF THE ECONOMIC CONSEQUENCES OF ADDING MANAGED VENTRICULAR PACING MODE (DDDR-MVP) TO A STANDARD DUAL CHAMBER PACEMAKER (DDDR) IN FRANCE Deniz HB, Caro JJ, Ward AJ Caro Research Institute, Concord, MA, USA Utility Based Patient Reported Outcomes UB1 MAPPING FROM DISEASE SPECIFIC MEASURES TO UTILITY: ALGORITHMS FOR ESTIMATING EQ-5D AND SF-6D VALUES FROM THE INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE IN PATIENTS WITH CROHN'S DISEASE Buxton M1, Lacey L2, Niecko T3, Miller D4, Townsend R4 1 Brunel University, Uxbridge, United Kingdom; 2 Lacey Solutions Ltd, Co Dublin, Ireland; 3 Niecko Health Economics, Escondido, CA, USA; 4 Elan Pharmaceuticals, San Diego, CA, USA UB2 QUANTIFYING THE RELATIONSHIP BETWEEN DISEASE SEVERITY, UTILITY AND HEALTH CARE RESOURCE USE IN CROHN'S DISEASE Weston AR1, Gibson PR2, Florin T3, Macrae F4, Radford-Smith G5, Shann A6, Lawrance I7 1 Health Technology Analysts Pty Ltd, Sydney, NSW, Australia; 2 Box Hill Hospital, Box Hill, VIC, Australia; 3 Mater Health Services Adult Hospital, Brisbane, QLD, Australia; 4 The Royal Melbourne Hospital, Melbourne, VIC, Australia; 5 Royal Brisbane Hospital, Brisbane, QLD, Australia; 6 Schering-Plough, Sydney, NSW, Australia; 7 Fremantle Hospital, Fremantle, WA, Australia UB3 A COMPARISON OF THE EQ-5D AND THE SF-6D IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION Brown MC Pfizer Limited, Sandwich, Kent, United Kingdom UB4 DETERMINANTS OF HEALTH STATE UTILITY IN PATIENTS WITH PSORIATIC ARTHRITIS Anis AH1, Guh D2, Bansback NJ2, Melilli LE3 1 University of British Columbia, Vancouver, BC, Canada; 2 Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada; 3 Abbott Laboratories, Abbott Park, IL, USA Cost Evaluation Studies In Urologic And Hematologic Diseases UH1 COST AND QUALITY OF LIFE OF HEMOPHILIA: COMPARISON BETWEEN PATIENTS WITH AND PATIENTS WITHOUT INHIBITORS Scalone L1, Gringeri A2, Mannucci PM2, Von Mackensen S3, Mantovani LG1 1 Center of Pharmacoeconomics, Milan, Italy; 2 Haemophilia and Thrombosis Centre, Milan, Italy; 3 Institute for Medical Psychology, Hamburg, Germany UH2 COST DRIVERS IN MULTIPLE MYELOMA TREATMENT – A 2 YEAR ANALYSIS FROM A MULTICOUNTRY RETROPROJECTED CHART REVIEW Moeremans K1, Caekelbergh K1, Spaepen E1, Annemans L1, Dhawan R2 1 IMS Health, Brussels, Belgium; 2 Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA UH3 OVERACTIVE BLADDER IN MALES: A GROWING HEALTH AND ECONOMIC BURDEN Reeves P1, Kopp Z2, Milsom I3, Artibani W4, Abrams P5 1 Fourth Hurdle Consulting Ltd, London, United Kingdom; 2 Pfizer Inc, New York, NY, USA; 3 Sahlgrenska University Hospital, Göteborg, Sweden; 4 Monoblocco Ospedaliero, Padova, Italy; 5 Bristol Urological Institute, BRISTOL, United Kingdom UH4 CHARACTERISTICS RELATED TO PRODUCTIVITY LOSS IN PATIENTS WITH OVERACTIVE BLADDER: RESULTS FROM THE MATRIX STUDY Pizzi LT1, Gemmen E2, Dahl NV3 1 Jefferson Medical College, Philadelphia, PA, USA; 2 Quintiles, Falls Church, VA, USA; 3 Watson Laboratories, Morristown, NJ, USA
18:00 - 20:00	Exhibitors' Open House Reception, Poster Presentations- Session I
	ISPOR 10th ANNIVERSARY PARTY